5 Recommendations for data collection

5 Recommendations for data collection

5.1 Proposals for further data collection in the Cancer Drugs Fund include:

  • recurrence-free survival

  • overall survival

  • long-term follow‑up of people who had nivolumab as an adjuvant treatment who develop advanced disease and have nivolumab again to treat metastatic disease.

  • National Institute for Health and Care Excellence (NICE)